Abiraterone - CYP17 inhibitor Abiraterone (CB-7598). CAS# 154229-19-3 one Demethylase LY3200882 inhibits NIH3T3 cell viability

LY3200882 inhibits NIH3T3 cell viability with an IC50 of 82

Smiles: O=C1C=C(OC2=C1C=CC=C2C1C=CC=CC=1)N1CCOCC1

InChi: InChI=1S/C13H8N2O3/c16-12-8-4-3-7-2-1-5-14-10(7)11(8)15-6-9(12)13(17)18/h1-6H

Compound list:  (+)-JQ1

135897-06-2

Abiraterone - CYP17 inhibitor Abiraterone (CB-7598). CAS# 154229-19-3 one Demethylase LY3200882 inhibits NIH3T3 cell viabilityAbiraterone, CAS No. 154229 19 3, is the first in class potent and selective CYP17 (cytochrome P450 17alpha hydroxylase 17, 20 lyase) inhibitor with IC50 ~4 nM. It was approved by US FDA in 2011 to treat castration resistant prostate cancer. As prostate cancer cells proliferate in response to androgen steroids, CYP17 inhibition is a new strategy to prevent androgen synthesis and treat lethal metastatic prostate cancer. In recent Nature publication,